Floatz logo

Dexmedetomidine

Liver Cancer

Uppsala University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

110 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Adriamycin
Shanghai Zhongshan Hospital
Phase 4BB
Xaliplatin
Sun Yat-sen University
Phase 3BB
Sufentanyl
The Second Affiliated Hospital of Chongqing Medical University
Phase 4BB
Sorafenib
First Affiliated Hospital Xi'an Jiaotong University
Phase 3BB
Tranexamic Acid
Konkuk University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Dexmedetomidine is also rated in:

schizophreniform disorderActive
A
Indicative · Phase 4
80 / 100
View asset →
schizoaffective disorderActive
BBB
Indicative · Phase 4
77 / 100
View asset →
neuralgiaActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →